<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="168202">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01948999</url>
  </required_header>
  <id_info>
    <org_study_id>N-20100085</org_study_id>
    <nct_id>NCT01948999</nct_id>
  </id_info>
  <brief_title>Electroconvulsive Therapy for Treatment Refractory Schizophrenia - A Randomized, Double-blinded, Sham-controlled Study</brief_title>
  <official_title>Electroconvulsive Therapy for Treatment Refractory Schizophrenia - A Randomized, Double-blinded, Sham-controlled Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Aarhus</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Aarhus</source>
  <oversight_info>
    <authority>Denmark: The National Committee on Health Research Ethics</authority>
    <authority>Denmark: Danish Dataprotection Agency</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to determine whether addition of electroconvulsive therapy to
      antipsychotic treatment improves the mental health of patients with treatment-resistant
      schizophrenia.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2013</start_date>
  <completion_date type="Anticipated">September 2016</completion_date>
  <primary_completion_date type="Anticipated">September 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Reduction in total PANSS score and adverse events</measure>
    <time_frame>The primary outcome will be assessed at screening, baseline and after every second week up to 72 weeks depending on the process for the individaul participant.</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>PANSS = Positive and Negative Syndrome Scale and UKU = The UKU (Udvalg for Kliniske Unders√∏gelser) side effect rating scale</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">70</enrollment>
  <condition>Treatment-refractory Schizophrenia</condition>
  <arm_group>
    <arm_group_label>ECT</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Electroconvulsive Therapy Anesthesia and concomitant muscular paralysis</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SHAM ECT</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Anesthesia and concomitant muscular paralysis</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>ECT</intervention_name>
    <arm_group_label>ECT</arm_group_label>
    <other_name>Eletroconvulsive Therapy inclusive anesthesia and concomitan muscular paralysis</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>SHAM ECT</intervention_name>
    <arm_group_label>SHAM ECT</arm_group_label>
    <other_name>Anesthesia and concomitan muscular paralysis</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Anesthesia</intervention_name>
    <arm_group_label>ECT</arm_group_label>
    <arm_group_label>SHAM ECT</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  An ICD-10 schizophrenia diagnosis F20.0-20.3 or F20.9

          -  PANSS total score &gt;= 70

          -  CGI-S &gt;= 4 (Clinical Global Impression)

          -  PANSS score &gt;= 4 on minimum 2 og the following items: Delusions, Conceptual
             disorganization,Hallucinatory behavior, Excitement, Grandiosity, Suspiciousness,
             Hostility, Disorientation.

          -  Previous/current treated with clozapine or refused clozapine treatment

          -  Lack of response to at least three different antipsychotics

          -  New antipsychotic medication prescribed more than 8 weeks before inclusion

          -  Fixed dosage of antipsychotics 1 month before inclusion

          -  No chance of additional neurotropic 4 weeks before inclusion

          -  Signed informed consent and power of attorney

        Exclusion Criteria:

          -  Significant substance abuse

          -  Somatic disease that increases the risk of complications of ECT/anesthesia

          -  Epilepsy

          -  For women: Pregnancy or breast-feeding

          -  Homelessness

          -  Use of benzodiazepines (apart from tbl. oxazepam 10 mg., max 30 mg. daily)

          -  Use of antiepileptic

          -  Previous no effect on psychotic symptoms after ECT treatment (minimum 15 ECT-
             treatments)

          -  Concrete suicidal plans
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jimmi Nielsen, M.D.</last_name>
    <phone>+4525779926</phone>
    <email>jin@rn.dk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Sonja Snel, M.D.</last_name>
    <phone>+4597643563</phone>
    <email>s.snel@rn.dk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Aalborg University Hospital, Aalborg Psychiatric Hospital, Centre for Schizophrenia</name>
      <address>
        <city>Aalborg</city>
        <zip>9220</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jimmi Nielsen, M.D.</last_name>
      <phone>+4525779926</phone>
      <email>jin@rn.dk</email>
    </contact>
    <contact_backup>
      <last_name>Benjamin Sneider, M.D</last_name>
      <phone>+4530339298</phone>
      <email>besn@rn.dk</email>
    </contact_backup>
    <investigator>
      <last_name>Jimmi Nielsen, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>September 2013</verification_date>
  <lastchanged_date>May 30, 2014</lastchanged_date>
  <firstreceived_date>June 17, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>electroconvulsive therapy</keyword>
  <keyword>treatment-refractory schizophrenia</keyword>
  <keyword>electroconvulsive therapy in treatment-refractory schizophrenia</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Schizophrenia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Anesthetics</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
